Redx excited over potential cancer treatment

Redx excited over potential cancer treatment

REDX, the Liverpool and Cheshire-based drug discovery and development company, says has identified an exciting potential treatment for hard-to-treat cancers. The drug, if it progresses through human trials, could be an affective alternative treatment to cancer in the pancreas, ‘triple negative’ breast and head and neck cancers.

A statement said: “Redx believes the superior characteristics of the company’s compound could result in a best-in-class drug, making the commercial potential for this new development candidate particularly attractive.”

Chief executive Dr Neil Murray, added: “We’re delighted to be announcing the fourth drug candidate to make it through our development pipeline. Our novel Porcupine inhibitor has the potential to tackle some of the most hard-to-treat cancers and we are particularly excited by the prospects for this target in immuno-oncology.

See the article in full at BusinessDesk.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.